Myeloproliferative Neoplasms News

Older adults diagnosed with a blood cancer exhibited similar rates of cognitive decline as cancer-free controls, according to study results.

Older cancer survivors exhibited increased risk for cardiovascular disease than cancer-free individuals of the same age, according to a secondary analysis of a randomized study.

Risk for myeloproliferative neoplasms among U.S. veterans increased significantly over time, according to retrospective study results.

Spouses of people with cancer exhibited significantly higher risk for attempted suicide and suicide death than those whose spouses had not been diagnosed with cancer, according to a nationwide cohort study in Denmark.

FDA has scaled back its Risk Evaluation and Mitigation Strategy reporting requirements for providers of chimeric antigen receptor T-cell therapies.

In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, discusses what she would like to see in the future of myleoproliferate neoplasms care and management.

In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, highlights unmet needs in myeloproliferate neoplasms care and management.

In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, explains why it is important to consider how myeloproliferative neoplasms treatment will affect a patient's quality of life.

In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, discussed the different approaches to treating different types of MPNs, like myelofibrosis, essential thrombocythemia and polycythemia vera.